The possible involvement of VEGF-A in tumor resistance to anti-PD-1 therapy has been reported[50], underscoring the fact that VEGF-A upregulation might be another mechanism employed by tumor cells in resistance to ICI therapy. The gene discussed is PDCD1; the disease is neoplasm.